Coverage of antibodies with modified glycosylation, focusing on production methods and effector function.
Afucosylated antibodies boost ADCC by enhancing FcγRIIIa binding on NK cells. Biointron highlights their engineering, clinical approvals, and growing therapeutic applications.
Fc glycans regulate antibody activity. Biointron reviews their role in modulating immune function and therapeutic antibody efficacy.
Discover how afucosylated antibodies enhance ADCC by increasing FcγRIIIa binding affinity, with clinical examples and applications in oncology and autoimmune disease therapy.
You can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.
